Canakinumab, an IL-1β antibody, effectively suppressed hsCRP and IL-6 but did not significantly affect fasting plasma glucose levels, insulin resistance, or the risk of diabetes development in the CANTOS trial. This evidence concerns the gene IL1B and Insulin resistance.